Oura Inc.
No enriched coverage for $OURA in the last 7 days.
No SEC Form 4 filings for $OURA in the last 30 days.
See all $OURA insider activity →Oura, a sleep-tracking ring company, postponed its IPO despite a 99% predicted chance, citing market conditions. It reported $1.2B revenue and $60.8M net income for 2026. The delay reflects broader IPO market slowdown, with only 30 U.S. IPOs in Q3 2026, down from 64 in 2025.
Oura expands GLP-1 Insights feature to 30+ markets, tracking user responses to weight-loss drugs like Ozempic and Wegovy. The feature logs manual and automatic health data but is not a medical device. Oura postponed its Nasdaq IPO, citing market uncertainty, despite strong revenue growth. Competitors like Whoop, Apple, and Samsung also offer health tracking features.
Oura postponed its IPO, highlighting privacy concerns in the AI wearables market. Apple, Google, and Meta face challenges as 67% of consumers worry about biometric data usage. EU regulators are preparing new guidelines, and companies are adapting with on-device processing and data deletion options.
Recent OURA coverage spans ipo and financial news.
Oura, a sleep-tracking ring company, postponed its IPO despite a 99% predicted chance, citing market conditions. It reported $1.2B revenue and $60.8M net income for 2026. The delay reflects broader IPO market slowdown, with only 30 U.S. IPOs in Q3 2026, down from 64 in 2025.
Oura expands GLP-1 Insights feature to 30+ markets, tracking user responses to weight-loss drugs like Ozempic and Wegovy. The feature logs manual and automatic health data but is not a medical device. Oura postponed its Nasdaq IPO, citing market uncertainty, despite strong revenue growth. Competitors like Whoop, Apple, and Samsung also offer health tracking features.
Oura postponed its IPO, highlighting privacy concerns in the AI wearables market. Apple, Google, and Meta face challenges as 67% of consumers worry about biometric data usage. EU regulators are preparing new guidelines, and companies are adapting with on-device processing and data deletion options.
Postponement removes near‑term supply of shares and signals market uncertainty.
Oura Inc. (OURA) postponed its IPO due to market volatility and investor concerns over its $15.6B valuation and aggressive growth projections. The company targets 90% YoY revenue growth in 2026, but macroeconomic challenges have dampened investor enthusiasm. Oura develops health-monitoring wearables, with the U.S. as its largest market.
AlphAI scores every news story that mentions OURA with an AI model for sentiment and relevance, and aggregates insider trades from Oura Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oura, a sleep-tracking ring company, postponed its IPO despite a 99% predicted chance, citing market conditions. It reported $1.2B revenue and $60.8M net income for 2026. The delay reflects broader IPO market slowdown, with only 30 U.S. IPOs in Q3 2026, down from 64 in 2025.
2 min readOura expands GLP-1 Insights feature to 30+ markets, tracking user responses to weight-loss drugs like Ozempic and Wegovy. The feature logs manual and automatic health data but is not a medical device. Oura postponed its Nasdaq IPO, citing market uncertainty, despite strong revenue growth. Competitors like Whoop, Apple, and Samsung also offer health tracking features.
2 min readOura postponed its IPO, highlighting privacy concerns in the AI wearables market. Apple, Google, and Meta face challenges as 67% of consumers worry about biometric data usage. EU regulators are preparing new guidelines, and companies are adapting with on-device processing and data deletion options.
2 min readOura postponed its $2.1B IPO citing market uncertainty, despite strong demand. Accelevation (ACCV) priced below range, raising $540M. Roze AI (RZAI) completed direct listing, up 149%. Six SPACs and three IPOs filed. Renaissance IPO Index up 16.4% YTD.
2 min readOura Inc. (OURA) postponed its IPO due to market volatility and investor concerns over its $15.6B valuation and aggressive growth projections. The company targets 90% YoY revenue growth in 2026, but macroeconomic challenges have dampened investor enthusiasm. Oura develops health-monitoring wearables, with the U.S. as its largest market.
3 min readAnthropic, developer of Claude, targets IPO this year with $4.6B revenue, $42B net loss, and $518B infrastructure commitment. REDLattice to list via SPAC at $1.25B valuation. Oura postpones IPO due to market uncertainty despite strong financials.
1 min readOura, maker of the Oura smart ring, delayed its $2.2B IPO despite strong demand, valuing it at up to $15B. The company planned to offer 50M shares at $40-$44 each but chose to wait due to market conditions. It would have listed on Nasdaq under the ticker OURA.
2 min readOura's IPO was delayed after seeking $2.2B at $40-$44 per share. Analyst David Tuckwell attributed this to high valuation expectations and competition from Apple. Oura has 5.7M paying members and expects 90% revenue growth. Rising interest rates and investor scrutiny are impacting IPO valuations, with focus shifting to fair pricing and quality deals.
3 min readOura, a health-monitoring smart-ring company, delayed its Nasdaq IPO a day before its planned listing on September 30, citing market uncertainty. The company had aimed to price shares between $40 and $44, with 50 million shares on offer. CEO Tom Hale stated demand is growing but the company chose to delay. Oura tracks health metrics and has 5.7 million paid members as of June. The delay follows broader IPO market slowdowns and AI safety concerns.
2 min readOura postponed its IPO, citing market uncertainty, despite strong demand. Anthropic's IPO prospectus revealed $4.6B revenue and $8.06B operating loss in 2025. The company has $518B in future obligations. Anthropic aims to IPO before rival OpenAI, potentially in October, raising up to $100B. Other companies like Nscale, Fidelis, and Switch are also preparing for IPOs.
2 min read
